搜索结果


   PPARGC1A

靶点ID:TCMBANKGE001149


靶点别名:LEM6; PGC-1(alpha); PGC-1alpha; PGC-1v; PGC1; PGC1A; PPARGC1


靶点描述:PPARG coactivator 1 alpha


染色体:4


染色体位置:4p15.2


靶点类型:protein-coding


HERB_ID:-


HGNC_Link:9237


OMIM_Link:604517


Ensembl_Link:ENSG00000109819


   靶点对应的植物
ID 拉丁名 药名 药用植物名 功能与主治 来源 药用部位 使用民族

   靶点对应的化合物
化合物ID 化合物名 别名 分子式 分子质量 Smiles
TCMBANKIN000052 cannabidiol abn-cbd, (-)-4-(3-3,4-trans-p-menthadien-[1,8]-yl)olivetol; SCHEMBL16224872 C21H30O2 314.5 g/mol CCCCCC1=CC(=C(C(=C1)O)C2C=C(CCC2C(=C)C)C)O
TCMBANKIN000065 dioscin LMST01080053; C08897; 3-O-(Rhaa1-4(Rhaa1-2)Glcb)-(25R)-spirost-5-en-3beta-ol; dioscin ; 19057-60-4; Dioscin C45H72O16 869.04 CC1CCC2(C(C3C(O2)CC4C3(CCC5C4CC=C6C5(CCC(C6)OC7C(C(C(C(O7)CO)OC8C(C(C(C(O8)C)O)O)O)O)OC9C(C(C(C(O9)C)O)O)O)C)C)C)OC1
TCMBANKIN000094 choline Choline chloride; choline hydroxide C5H14NO+ 104.17 g/mol C[N+](C)(C)CCO
TCMBANKIN000109 myricanol C21H26O5 358.4 g/mol COC1=C2C=C(CCCCC(CCC3=CC2=C(C=C3)O)O)C(=C1OC)O
TCMBANKIN003739 1,4-heptadiene C7H12 96.17 g/mol CCC=CCC=C
TCMBANKIN017939 α-lindane C6H6Cl6 or ClCH(CHCl)4CHCl C1(C(C(C(C(C1Cl)Cl)Cl)Cl)Cl)Cl
TCMBANKIN022090 oxalaceticacid C4H4O5 132.07 g/mol C(C(=O)C(=O)O)C(=O)O
TCMBANKIN036795 punicalagin punicalagin C48H28O30 1085 c1(O[H])c(O[H])c(c2c3c(c4c(O[H])c2O[H])c(c(c(c5c([H])c(C(=O)OC([H])([H])[C@]6([H])[C@@]([H])(OC7=O)[C@@]8([H])[C@@]([H])(OC(=O)c(c([H])c(O[H])c(O[H])c9O[H])c9c(c(C(=O)O8)c([H])c%10O[H])c(O[H])c%10O[H] )[C@]([H])(O[H])O6)c(O[H])c(O[H])c5O[H])c(O[H])c%11O[H])C(=O)O4)c%11OC3=O)c7c([H])c1O[H]
TCMBANKIN036824 2,3,5,4'-Tetrahydroxystilbene-2-O-β-D-glucoside 2,3,5,4'-tetrahydroxystilbene-2-o-beta-d-glucoside 406.4 g/mol
TCMBANKIN049920 alpha-Lipoic acid α-lipoicacid; 5-[1,2]-dithiolan-3-yl-pentanoic acid C8H14O2S2 206.326 C1([H])([H])C([H])([H])[C@]([H])(SS1)C([H])([H])C([H])([H])C([H])([H])C([H])([H])C(=O)O[H]
TCMBANKIN057899 arsenicum;arsenic;as As 74.92159 g/mol [As]
TCMBANKIN058205 trans-resveratrol (E)-1-(3,5-dihydroxyphenyl)-2-(4-hydroxyphenyl)ethene; SRT501; AX8004672; DB02709; RP17549; NCGC00017352-05; NCGC00017352-13; NCGC00017352-19; (E)-5-(2-(4-hydroxyphenyl)ethenyl)-1,3-benzenediol; 4CN-0696; I06-0437; 3,4',5-Trihydroxy-trans-stilbene; (E)-5-[2-(4-Hydroxyphenyl)ethenyl]-1,3-benzenediol; s1396; HMS1990H15; SAM001246888; CPD000058206; CU-01000001503-3; BPBio1_000479; NCGC00024003-14; (E)-5-(p-Hydroxystyryl)resorcinol; FT-0082623; Tox21_501111; 5-[(1E)-2-(4-Hydroxyphenyl)ethenyl]-1,3-benzenediol; 01R360; 5-[2-(4-hydroxyphenyl)ethenyl]benzene-1,3-diol; Tox21_303376; MLS001055357; NCGC00024003-13; GP5884; A827984; resveratrol; NCGC00017352-09; NCGC00017352-15; 5-[(E)-2-(4-hydroxyphenyl)ethenyl]benzene-1,3-diol; NCGC00024003-11; D0U3EP; ACN-034773; ST057251; EU-0101111; InChI=1/C14H12O3/c15-12-5-3-10(4-6-12)1-2-11-7-13(16)9-14(17)8-11/h1-9,15-17H/b2-1; HY-16561; N1848; ACT09778; NCGC00017352-17; BRD-K80738081-001-09-6; KUC104385N; 3,4',5-Trihydroxy-trans-stilbene 5-[(1E)-2-(4-hydroxyphenyl)ethenyl]-1,3-benzenediol; 5-[(E)-2-(4-hydroxyphenyl)ethenyl]-1,3-benzenediol; LUKBXSAWLPMMSZ-OWOJBTEDSA-N; STL; MLS001424228; 5-[(E)-2-(4-Hydroxyphenyl)vinyl]-1,3-benzoldiol; 5-[(E)-2-(4-Hydroxyphenyl)vinyl]-1,3-benzenediol; HMS1569F17; Resveratrol, Vetec(TM) reagent grade, 98%; HMS1921N04; IDI1_002152; Resvida; KB-02515; SR-01000000163-10; NCGC00017352-08; AB00052942_31; 3,5,4'-Trihydroxystilbene; trans-Stilbene-3,4',5-triol; Tox21_110257; NCGC00024003-12; trans-3,4′,5-Trihydroxystilbene; trans-3,4',5 - trihydroxystilbene; ZB000650; ZINC6787; DSSTox_RID_78898; NCGC00024003-09; 3fts; BB_NC-2570; SRT-501; ZX-AS004941; 5-[(E)-2-(4-Hydroxyphenyl)ethenyl]benzol-1,3-diol; BRD-K80738081-001-23-7; trans-1,2-(3,4',5-Trihydroxydiphenyl)ethylene; NSC327430; LS-2146; (E)-5-(4-Hydroxystyryl)benzene-1,3-diol; NCGC00024003-04; DSSTox_CID_11980; 5-[(1E)-2-(4-Hydroxyphenyl)ethenyl]-1,3,benzenediol; Prestwick3_000508; trans-Resveratrol, United States Pharmacopeia (USP) Reference Standard; Resveratrol, European Pharmacopoeia (EP) Reference Standard; NCGC00015894-02; ARONIS24568; STL146386; R 5010; 1,3-Benzenediol, 5-(2-(4-hydroxyphenyl)ethenyl)-, (E)-; AC1L9HIC; BSPBio_003461; REGID_for_CID_445154; C14H12O3; SR-01000000163-11; 501-36-0; C03582; SRT 501; NSC 327430; NSC-327430; Spectrum5_000552; AS-12413; Trans-3,4′ NCGC00024003-06; AKOS005720936; BG01529320; BBC/741; HMS1792H15; NCGC00258925-01; TL8003323; AB00052942-29; SR-01000000163-4; SR-01000000163-16; BSPBio_000435; Opera_ID_586; NC00349; 1,3-Benzenediol, 5-[(1E)-2-(4-hydroxyphenyl)ethenyl]-; ZX-AT013797; 375823-41-9; HMS3403H15; 3,4',5-Trihydroxystilbene; HMS2232A18; KSC-10-164; AN-865; LMPK13090005; AJ-08292; OR46018; R0071; CHEMBL165; BRD-K25591257-001-01-2; Resveratrol, E-; BBL028252; NCGC00024003-05; LP01111; UNII-Q369O8926L; CCG-38874; (E)-5-[2-(4-hydroxyphenyl)ethenyl]-1,3-benzendiol; MFCD00133799; 2l98; BDBM23926; SGCUT00007; GP2549; Resveratrol, trans-; CC-34242; ST2408097; MLS001076538; AK-39118; HMS1362H15; NCGC00024003-07; ABP000376; SBB055452; NCGC00017352-16; trans-3,5,4'-Trihydroxystilbene3,4',5-Stilbenetrioltrans-Resveratrol(E)-5-(p-Hydroxystyryl)resorcinol(E)-5-(4-hydroxystyryl)benzene-1,3-diol; 5-[(1E)-2-(4-hydroxyphenyl)vinyl]benzene-1,3-diol; Tox21_110257_1; BRD-K80738081-001-06-2; Resveratrol, certified reference material, TraceCERT(R); 3,4',5-Stilbenetriol; MCULE-5678456463; J10118; BSPBio_001114; HMS2052I09; Resveratrol, >=99% (HPLC); CS-1050; SCHEMBL19425; 5[(E)-2-(4-Hydroxyphenyl)-vinyl]benzene 1,3-diol; Resveratol; (E)1-(3,5-dihydroxyphenyl)-2-(4-hydroxyphenyl)ethene; HMS3263O04; 4jaz; AB0006623; CAS-501-36-0; CCRIS 8952; MLS000069735; trans-3,4',5-trihydroxystilbene; 4qer; Tox21_201374; to_000079; SPECTRUM1502223; BC202036; API0000480; NCGC00017352-10; CHEBI:27881; NCGC00017352-24; SY014849; 3,4',5-trihydroxy-stilbene; NCGC00017352-06; PREVENTION 8 (RESVERATROL); MolPort-002-499-801; (E)-resveratrol; BCPP000091; Prestwick_619; 5-((1E)-2-(4-Hydroxyphenyl)ethenyl)-1,3-benzenediol; SMR000058206; cid_445154; Q369O8926L; Resveratrol, analytical standard; DSSTox_GSID_31980; NCGC00017352-11; AC-727; HMS2096F17; BS0159; 5-[2-(4-hydroxyphenyl)vinyl]-1,3-benzenediol; BRD-K80738081-001-10-4; NCGC00017352-12; MLS002222231; Resveratrol, natural; Lopac0_001111; BR-39118; CJ-00111; NCGC00017352-07; DTXSID4031980; CR-003; Stilbene, 2f; NCGC00017352-18; NCGC00024003-10; SC-11924; SR-01000000163-3; MLS002207121; (E)-5-(2-(4-hydroxyphenyl)ethenyl)-1,3-benzenediol(E)-5-(2-(4-hydroxyphenyl)ethenyl)-1,3-benzenediol; NCGC00024003-00; HMS3649A20; KS-5047; 1,3-Benzenediol, 5-[(E)-2-(4-hydroxyphenyl)ethenyl]-; NCGC00017352-14; HSDB 7571; NCGC00024003-08; 533C1DA0-4104-42B5-9D32-9265F40857E4; RM-1812; REGID_for_CID_6240; 5-[(E)-2-(4-hydroxyphenyl)vinyl]benzene-1,3-diol; SDCCGMLS-0002998.P003; BIK9013; NCGC00257465-01; GTPL8741; BG00606847; NCGC00261796-01; CHEBI:45713; SR-01000000163; Resveratrol, synthetic; SR-01000000163-9; Prestwick2_000508; N88795; 3,5,4'-Trihydroxy-trans-stilbene; resveratrol; 1,3-Benzenediol, 5-((1Z)-2-(4-hydroxyphenyl)ethenyl)-; cis-3,5,4'-trihydroxystilbene; AIDS025474; (E)-5-(2-(4-hydroxyphenyl)ethenyl)-1,3-benzenediol; SPBio_002356; BPBio1_000479; 5-[(1E)-2-(4-Hydroxyphenyl)ethenyl]-1,3-benzenediol; 5-[2-(4-hydroxyphenyl)ethenyl]benzene-1,3-diol; 5-[(1E)-2-(4-hydroxyphenyl)ethenyl]benzene-1,3-diol; Spectrum4_001896; 5-[(E)-2-(4-hydroxyphenyl)ethenyl]benzene-1,3-diol; EU-0101111; ST057251; InChI=1/C14H12O3/c15-12-5-3-10(4-6-12)1-2-11-7-13(16)9-14(17)8-11/h1-9,15-17H/b2-1; resveratrol ; KBioSS_000454; 1684AH; Spectrum3_001821; STL; CHEBI:36002; SPBio_001513; IDI1_002152; Prestwick1_000508; 05F9DB2A-D7E6-4063-8E5B-F7842CF74A5E; 3,5,4'-Trihydroxystilbene; 3,4',5-trihydroxy stilbene; (Z)-resveratrol; 5-[(Z)-2-(4-hydroxyphenyl)vinyl]benzene-1,3-diol; trans-3,4′,5-Trihydroxystilbene; 31100-06-8; 5-[(1Z)-2-(4-hydroxyphenyl)ethenyl]benzene-1,3-diol; Cis resveratrol; SRT-501; NSC327430; 3,4′,5-Trihydroxy-trans-stilbene; Spectrum_001148; 5-[(1Z)-2-(4-Hydroxyphenyl)ethenyl]-1,3-benzenediol; NCGC00024003-04; Prestwick3_000508; NCGC00015894-02; Z-5-[2-(4-Hydroxyphenyl)ethenyl]-1,3-benzenediol; NCGC00017352-03; SCHEMBL1931746; 1,3-Benzenediol, 5-(2-(4-hydroxyphenyl)ethenyl)-, (E)-; BSPBio_003461; Bio2_000877; InChI=1/C14H12O3/c15-12-5-3-10(4-6-12)1-2-11-7-13(16)9-14(17)8-11/h1-9,15-17H/b2-1-; 31100-06-8 (DELETED); Z-Resveratrol; UNII-AUA0K06FSB; 501-36-0; C03582; AKOS025395422; KBio2_004196; KBio3_002965; Prestwick0_000508; NSC 327430; 34092_RIEDEL; KBio3_000848; NCGC00017352-02; Spectrum5_000552; MolPort-003-850-143; NCGC00024003-06; KBio2_005590; SpecPlus_000391; AC1LU7HY; AUA0K06FSB; KBioGR_000454; AIDS-025474; BSPBio_000435; cis-resveratrol; KBio2_006764; KBio2_001628; KBioGR_002457; CHEMBL87333; 3,4',5-Trihydroxystilbene; Lopac-R-5010; (E)-5-[2-(4-hydroxyphenyl)ethenyl]-1,3-benzendiol; KBio2_000454; Resveratrol, (Z)-; SGCUT00007; CJ-13797; NCGC00024003-07; Resveratrol (Z)-form [MI]; NCGC00017352-01; I14-7425; DivK1c_006487; MolMap_000045; 3,4',5-Stilbenetriol; Oprea1_727238; Tocris-1418; DB-072954; NCGC00017352-04; BSPBio_001114; BDBM50131698; 434C671; LUKBXSAWLPMMSZ-UPHRSURJSA-; KBio3_000847; CAS-501-36-0; SMP1_000257; 4q93; MLS000069735; cis-5-[2-(4-Hydroxyphenyl)ethenyl]benzene-1,3-diol; ZINC00006787; (Z)-3,5,4'-trihydroxystilbene; to_000079; SPECTRUM1502223; trans-Resveratrol; R5010_SIGMA; KBio2_003022; 61434-67-1; NCGC00024003-02; NCGC00015894-01; CHEBI:27881; Resveratrol; AC-24235; (E)-resveratrol; Prestwick_619; 5-[2-(4-hydroxyphenyl)vinyl]resorcinol; SMR000058206; TNP00294; Resveratrol, Z-; ZINC12353732; Lopac0_001111; cis-3,4',5-trihydroxystilbene; NCI60_002840; 5-[(E)-2-(4-hydroxyphenyl)vinyl]resorcinol; Bio2_000397; NCGC00024003-00; (Z)-3,4',5-trihydroxystilbene; 3,5-Dihydroxy-4'-methoxystilbene; 3, 5,4'-trihydroxy-trans-stilbene; cis-3,4,5-Trihydroxystilbene; NCGC00024003-08; RM-1812; 5-[(E)-2-(4-hydroxyphenyl)vinyl]benzene-1,3-diol; 5-[2-(4-hydroxyphenyl)vinyl]benzene-1,3-diol; SDCCGMLS-0002998.P003; KBioSS_001628; KBio1_001431; 5-[(Z)-2-(4-hydroxyphenyl)ethenyl]benzene-1,3-diol; CHEBI:45713; Spectrum2_001497; Prestwick2_000508; 3,5,4'-Trihydroxy-trans-stilbene C14H12O3 228.24 g/mol C1=CC(=CC=C1C=CC2=CC(=CC(=C2)O)O)O
TCMBANKIN058213 kaemferol;kampferol;kaempferol;campherol TNP00039; nchembio.2007.28-comp30; Kaempherol; 5-18-05-00251 (Beilstein Handbook Reference); Prestwick2_001098; CHEBI:28499; Prestwick1_001098; CAS-520-18-3; BRN 0304401; Flavone, 3,4',5,7-tetrahydroxy-; ST030560; MEGxp0_001283; 4H-1-Benzopyran-4-one, 3,5,7-trihydroxy-2-(4-hydroxyphenyl)-5,7,4'-Trihydroxyflavonol; C.I. 75640; Swartziol; K0133_SIGMA; kaempferol oxoanion; NCGC00016480-01; 60010_FLUKA; EINECS 208-287-6; Pelargidenon; Nimbecetin; 3,5,7-trihydroxy-2-(4-hydroxyphenyl)-4-chromenone; NSC 407289; 3,4',5,7-Tetrahydroxyflavone; HSCI1_000027; Pelargidenolon 1497; NSC407289; Robigenin; C05903; CPD1F-90; Kampferol; NSC 656277; Prestwick0_001098; 3,5,7-trihydroxy-2-(4-hydroxyphenyl)chromen-4-one; Populnetin; Kampcetin; Prestwick3_001098; AIDS-001404; ZINC00137345; kaempferol ; 5,7-dihydroxy-2-(4-hydroxyphenyl)-4-oxo-4H-chromen-3-olate; 3,4′,5,7-Tetrahydroxyflavone; Rhamnolutein; NCGC00016480-02; ACon1_001867; NSC656277; 3,4′,5,7-Tetrahydroxyflavone; BSPBio_001176; SPBio_003058; Oprea1_650954; 5,7,4'-Trihydroxyflavonol; 4H-1-Benzopyran-4-one,3,5,7-trihydroxy-2-(4-hydroxyphenyl)-5,7,4'-Trihydroxyflavonol; 4H-1-Benzopyran-4-one, 3,5,7-trihydroxy-2-(4-hydroxyphenyl)- (9CI); Campherol; 520-18-3; 3,5,7-TRIHYDROXY-2-(4-HYDROXYPHENYL)-4H-CHROMEN-4-ONE; S00111; Trifolitin; Kampherol; AI3-36096; 3,5,7-trihydroxy-2-(4-hydroxyphenyl)chromone; Indigo yellow; Pelargidenolon; AIDS001404; nchembio718-comp14; NCGC00091036-01; Flavone, 3,4',5,7-tetrahydroxy- (7CI,8CI); CHEBI:58573; Kaemferol; Kempferol; BPBio1_001294; 3,5,7-Trihydroxy-2-(4-hydroxyphenyl)-4H-1-benzopyran-4-one; Rhamnolutin; 3,5,7-triOH-Flavone; KMP; CCRIS 41; 4H-1-Benzopyran-4-one, 3,5,7-trihydroxy-2-(4-hydroxyphenyl)- C15H10O6 286.24 g/mol C1=CC(=CC=C1C2=C(C(=O)C3=C(C=C(C=C3O2)O)O)O)O
TCMBANKIN058267 vitamin b NSC169454; SR-01000722017-4; Nicotinic acid, >=98%; [3H]nicotinic acid; Nicotinamide (JP15/INN); AC1Q73P3; C6H5NO2; 11054-EP2289510A1; NCGC00094734-02; AB00052050; HMS3655K08; Efacin; Nico-400; N1103; 11054-EP2298772A1; TR-032523; C00253; Nicosan 3; SPBio_000011; Nicotinic Acid [Matrix for MALDI-TOF/MS]; SPBio_002881; 5-22-02-00057 (Beilstein Handbook Reference); Niacinamide Astra Brand; Spectrum3_000515; ANW-75276; Bionic; 11054-EP2301923A1; SDCCGMLS-0066610.P001; Nicotinsaure [German]; Nicotinic acid, >=99.5% (HPLC); preventative factor; 28029-53-0 (cobalt(2+) salt); SR-01000722017-3; Acide nicotinique [INN-French]; 11054-EP2295409A1; NICO; InChI=1/C6H5NO2/c8-6(9)5-2-1-3-7-4-5/h1-4H,(H,8,9; D00049; Jenapharm Brand of Niacinamide; Nicotinamide (TN); Niacin [USAN]; bmse000104; 1976-28-9 (aluminum salt); 11054-EP2311816A1; Apelagrin; AN-23622; KBio2_001543; ABT-919; Acido nicotinico; .beta.-Pyridinecarboxylic acid; Niaspan (TN); 11054-EP2270002A1; SR-01000722017-2; KB-33243; Pellagramin; NCGC00016268-02; DSSTox_CID_932; Merck Brand of Niacinamide; nicobid; beta-pyridinecarboxylic acid; BDBM23515; 3PyrCOOH; Nicotinic acid, BioReagent, suitable for cell culture, suitable for insect cell culture, suitable for plant cell culture, >=98%; Pellagra preventive factor; niacin; Prestwick0_000881; Nicotinic acid, Ph Eur; BPBio1_000730; Nicacid; UNII-2679MF687A; EBD2198325; NCGC00016268-08; 3-Carboxypyridine; ST097540; Z56755709; Davitamon PP; Nicotinamide (Niacinamide); Nicotinic acid, analytical standard; CPD000059024; 3-Pyridylcarboxylic acid; Pyridine-beta-carboxylic acid; KBioSS_001543; 11054-EP2305674A1; Nicotinic acid, for synthesis, 99%; Nicodon; Oprea1_514398; [5, 6-3H]-niacin; 636-79-3 (hydrochloride); Direktan; Niacin (Nicotinic Acid), Pharmaceutical Secondary Standard; Certified Reference Material; DB-007765; 11054-EP2298742A1; Nyclin; 11054-EP2316827A1; NSC-169454; 7069-06-9 (magnesium salt); 11054-EP2316826A1; Niacor; niacine; MLS000069603; AC-907/25014105; GTPL1594; Spectrum5_001287; RP00705; niacin potassium; BSPBio_002069; STR00112; IDI1_000695; LS-2334; AM81316; NAH; P.P. factor-pellagra preventive factor; AC-22484; Vitaplex N; Nicodan; 3789-96-6 (tartrate); 11054-EP2311829A1; AB1002056; Niacinamide Merck Brand; Spectrum4_000965; Pyridinecarboxylic acid, 3-; CCRIS 1902; 11054-EP2308838A1; SBI-0051456.P003; 11054-EP2280001A1; Nicotinic acid [INN]; PubChem2594; Nicovasen; 54-86-4 (hydrochloride salt); 11054-EP2274983A1; 11054-EP2308854A1; NCGC00016268-04; MCULE-3788394698; Nicagin; nicolar; NIASPAN TITRATION STARTER PACK; AB00052050-13; ST2413625; J-523605; 36321-41-2 (ammonium salt); Acido nicotinico [INN-Spanish]; Akotin; EINECS 200-441-0; SBB004279; 11054-EP2311830A1; Niacin, United States Pharmacopeia (USP) Reference Standard; Acidum nicotinicum; Nikasan; SR-01000722017; AK-46486; Enduracin; CS-1946; Nicotinic acid, certified reference material, TraceCERT(R); Induracin; Nico-Span; antipellagra vitamin; 3-pyridine carboxylic acid; Nicoside; Nicotinic acid, purum, >=99.0% (HPLC); CHEMBL573; Pyridylcarboxylic Acid; Tinic; 11054-EP2295424A1; EPA Pesticide Chemical Code 056701; Nicotine acid; Ncotnc acd; 11054-EP2305651A1; pellagra; Nicorol; 5-pyridinecarboxylic acid; NCGC00094734-01; 11054-EP2298776A1; 3-Picolinic acid; Niacin; Pellagra preventive factor; Pyridine-3-carboxylic acid; Vitamin B3; KBioGR_001309; 11054-EP2308848A1; KSC236Q9T; Nipellen; Niacin (USP); 3-pyridinecarboxylic acid; Vitamin B3 (Niacin); KBio2_006679; NCI60_001041; HMS2236A05; AB00052050_14; Nicotinic acid, matrix substance for MALDI-MS, >=99.5% (HPLC); HMS2097B04; Spectrum2_000006; 99148-57-9 (tosylate); SCHEMBL1433; BSPBio_000662; MolPort-000-142-273; KBio3_001569; 10361-13-4 (iron(2+) salt); Tox21_110337_1; F2191-0082; Acide nicotinique; Nicotinic acid, European Pharmacopoeia (EP) Reference Standard; 11054-EP2269990A1; 11054-EP2308858A1; M-5918; 11054-EP2275401A1; Nicotinic acid, plant cell culture tested; Nicotinic acid, SAJ special grade, >=99.5%; Niacinamide (TN); HMS3714B04; STK301803; Pelonin; Niconazid; Prestwick2_000881; Nicovasan; 11054-EP2270014A1; Niacinamide Pharmagenix Brand; Pharmakon1600-01500430; Pyridine-carboxylique-3 [French]; SK-Niacin; Prestwick1_000881; Nikazan; EC 200-441-0; PP Factor; AKOS000118980; HY-B0143; Tox21_110337; HMS3371E07; WLN: T6NJ CVQ; Nicotene; Nicotinic acid [INN:BAN]; CAS-59-67-6; 11054-EP2316458A1; Kyselina nikotinova [Czech]; P.P. factor; Pyridine-3-carboxylic acid; Niacin (nicotinic acid); Tox21_201420; L001199; NCGC00016268-09; nicocap; I02-0699; nicotinic acid; Niconat; ZINC1795; Niacin [USP]; Diacin; 11054-EP2272825A2; Kyselina nikotinova; FC1287; Nicotinic acid-d3(major); CHEBI:15940; 823-77-8 (calcium salt); Niacor (TN); DSSTox_RID_75875; NCGC00256537-01; Nicotamin; GTPL1588; 2679MF687A; ACMC-1AS6M; [3H]-Nicotinic acid; SPECTRUM1500430; Acidum nicotinicum [INN-Latin]; HMS1570B04; 11054-EP2301937A1; KBio1_000695; BP-21419; Niacinamide Jenapharm Brand; AJ-08093; Nicotinic acid, NIST(R) SRM(R) 148; niacin magnesium; Nicyl; S115; Tega-Span; 11054-EP2269610A2; KBio2_004111; AC1L1AD5; NCGC00016268-01; Niacinamide, Nicotinic acid amide, Nicotinamide; Opera_ID_1346; Nicotinic acid, 99% 250g; 3-Pyridyl carboxylic acid; Nicocidin; nicotinate; s1744; SR 4390; DTXSID1020932; Nicotinsaure; 16518-17-5 (potassium salt); Nicotinic acid, Vetec(TM) reagent grade, >=98%; 11054-EP2308839A1; Linic; BIDD:GT0644; NC00524; wampocap; NCGC00016268-03; Nicotinic acid, for inorganic trace analysis, >=99.999% (metals basis); AB00052050_15; Nicosyl; CCG-38340; D06NVJ; 11054-EP2301935A1; 11054-EP2308874A1; Nikotinsaeure; SC-05611; Pyridine-3-carbonic acid; Nicodelmine; 53890-72-5 (lithium salt); 11054-EP2311808A1; SMR000059024; Daskil; NSC 169454; MFCD00006391; PS-4255; HMS502C17; 11054-EP2272848A1; FT-0082580; Pyridine-.beta.-carboxylic acid; DivK1c_000695; 11054-EP2295406A1; Niacin-Vitamin B3; N0082; BRN 0109591; 3-Carboxylpyridine; 11054-EP2316828A1; Niac; NCGC00258971-01; 3-Picolinic acid; 11054-EP2292610A1; NINDS_000695; 11054-EP2292228A1; FT-0600004; Astra Brand of Niacinamide; Nicotinic Acid 1.0 mg/ml in Methanol; 11054-EP2272834A1; HMS3259K21; Niacin (TN); Nicotinic acid (JP17/INN); NSC-757241; Prestwick3_000881; Niaspan; Slo-niacin; SAM002554917; HMS2091H22; Pharmagenix Brand of Niacinamide; 59-67-6; NCGC00016268-05; Tox21_302904; Pellagrin; Caswell No. 598; 11054-EP2277848A1; 3DDB011E-F3A6-45B6-A2D2-77B2A6E8936E; 11054-EP2301929A1; 11054-EP2311817A1; Naotin; m-Pyridinecarboxylic acid; vitamin B3; HSDB 3134; Peviton; nicamin; Nicotinic acid (Vitamin B3) solution, 1.0 mg/mL in methanol, ampule of 1 mL, certified reference material; Nicangin; Spectrum_001063; Pyridine-carboxylique-3; KB-259513; 11054-EP2298779A1; Nicocrisina; DB00627; 11054-EP2316825A1; AI3-18994; PVNIIMVLHYAWGP-UHFFFAOYSA-N; 11054-EP2316457A1; I14-92791; anti-Pellagra vitamin; 28029-54-1 (manganese(2+) salt); NSC757241; 123574-58-3; Nicotil; HMS1920P17; Nicotinipca; 3-Pyridinecarboxylicacid; 11054-EP2314588A1; Niconacid; NIO; Nicotinic acid, meets USP testing specifications; DSSTox_GSID_20932; Nicotinamide-carbonyl-14C C5H4NCOOH 123.11 g/mol C1=CC(=CN=C1)C(=O)O
TCMBANKIN058450 ADO nchembio.2007.56-comp13; CHEBI:16335; Bio1_000437; 9-beta-D-Ribofuranosyl-9H-purin-6-amine; AIDS-001224; 9beta-D-Ribofuranosyladenine; BSPBio_001796; beta-Adenosine; (2R,3R,4S,5R)-2-(6-aminopurin-9-yl)-5-methylol-tetrahydrofuran-3,4-diol; beta-D-Ribofuranoside, adenine-9; D00045; 46969-16-8; SDCCGMLS-0003108.P003; 4-Aminopyrazolo[3,4-d]pyrimidine ribonucleoside; (2R,3R,4S,5R)-2-(6-aminopurin-9-yl)-5-(hydroxymethyl)oxolane-3,4-diol; 6-Amino-9-.beta.-ribofuranosyl-9H-purine; NSC 7652; Bio1_001415; Adenosine (JAN/USP); Spectrum2_001257; Spectrum3_000288; Adenosine, homopolymer; ADN; Caswell No. 010B; Adenocard; C00212; SR 96225; Adenocard (TN); EINECS 200-389-9; KBio3_001296; 9H-Purin-6-amine, 9beta-D-ribofuranosyl-; Polyadenosine; beta-D-Ribofuranose, 1-(6-amino-9H-purin-9-yl)-1-deoxy-; (2R,3R,4S,5R)-2-(6-amino-9-purinyl)-5-(hydroxymethyl)tetrahydrofuran-3,4-diol; MLS000069638; AI3-52413; 9-beta-D-Ribofuranosidoadenine; A9251_SIGMA; Adenoscan (TN); Bio1_000926; ZINC02169830; CCRIS 2557; NCGC00023673-05; Ade-Rib; nchembio706-5; 30143-02-3; 6-Amino-9-beta-D-ribofuranosyl-9H-purine; Adenosin [German]; NSC 627048; SMR000058216; 9-beta-D-Ribofuranosyladenine; SPBio_001194; beta-D-Adenosine; Adenosine [USAN:BAN]; Polyriboadenosine; (2R,3R,4S,5R)-2-(6-aminopurin-9-yl)-5-(hydroxymethyl)tetrahydrofuran-3,4-diol; AIDS001224; 6-Amino-9beta-D-ribofuranosyl-9H-purine; ST009496; Adenoscan; A4036_SIGMA; SPECTRUM1500107; 46946-45-6;SCHEMBL170902; adenosine ; AKOS015960342; AC-5504; BC200893; Adenosine;adenosine;adeninenucleoside C10H13N5O4 267.24 g/mol C1=NC(=C2C(=N1)N(C=N2)C3C(C(C(O3)CO)O)O)N
TCMBANKIN059947 vitamin b1 C63H88CoN14O14P 1356.4 g/mol CC1=CC2=C(C=C1C)N(C=N2)C3C(C(C(O3)CO)OP(=O)(O)OC(C)CNC(=O)CCC4(C(C5C6(C(C(C(=N6)C(=C7C(C(C(=N7)C=C8C(C(C(=N8)C(=C4[N-]5)C)CCC(=O)N)(C)C)CCC(=O)N)(C)CC(=O)N)C)CCC(=O)N)(C)CC(=O)N)C)CC(=O)N)C)O.[C-]#N.[Co+2]
TCMBANKIN059948 Vitamin- G C17H20N4O6 376.36 CC1=CC2=C(C=C1C)N(C3=NC(=O)NC(=O)C3=N2)CC(C(C(CO)O)O)O
TCMBANKIN060161 afzelin C21H20O10 432.4 g/mol CC1C(C(C(C(O1)OC2=C(OC3=CC(=CC(=C3C2=O)O)O)C4=CC=C(C=C4)O)O)O)O
TCMBANKIN060264 rutin C27H30O16 610.5 g/mol CC1C(C(C(C(O1)OCC2C(C(C(C(O2)OC3=C(OC4=CC(=CC(=C4C3=O)O)O)C5=CC(=C(C=C5)O)O)O)O)O)O)O)O
TCMBANKIN060497 dioscin C45H72O16 869.04 CC1CCC2(C(C3C(O2)CC4C3(CCC5C4CC=C6C5(CCC(C6)OC7C(C(C(C(O7)CO)OC8C(C(C(C(O8)C)O)O)O)O)OC9C(C(C(C(O9)C)O)O)O)C)C)C)OC1
TCMBANKIN060879 Linolic acid C18H32O2 280.4 g/mol CCCCCC=CCC=CCCCCCCCC(=O)O
TCMBANKIN060958 oleic acid;cis-oleic acid;oleinic acid C18H34O2 282.46 CCCCCCCCC=CCCCCCCCC(=O)O
TCMBANKIN060980 caproic acid;capric acid;n-decanoic acid;NON C10H20O2 172.26 g/mol CCCCCCCCCC(=O)O
TCMBANKIN061006 lauric acid C12H24O2 200.32 CCCCCCCCCCCC(=O)O
TCMBANKIN061029 myristic acid C14H28O2 228.37 CCCCCCCCCCCCCC(=O)O
TCMBANKIN061091 stearic acid CH3(CH2)16COOH 284.5 g/mol CCCCCCCCCCCCCCCCCC(=O)O

   靶点对应的疾病
疾病ID 疾病名 MeSH名 HPO名 UMLS名 疾病类型
TCMBANKDI000049 Congenital, Hereditary, and Neonatal Diseases and Abnormalities; Female Urogenital Diseases and Pregnancy Complications; Male Urogenital Diseases - Disease or Syndrome disease
TCMBANKDI000054 Nervous System Diseases; Mental Disorders Abnormality of the nervous system Disease or Syndrome disease
TCMBANKDI000071 Digestive System Diseases; Chemically-Induced Disorders - Disease or Syndrome disease
TCMBANKDI000092 Respiratory Tract Diseases Abnormality of the respiratory system Disease or Syndrome disease
TCMBANKDI000166 - - Neoplastic Process disease
TCMBANKDI001057 Cardiovascular Diseases Abnormality of the cardiovascular system Disease or Syndrome disease
TCMBANKDI001779 Digestive System Diseases Abnormality of the digestive system Disease or Syndrome disease
TCMBANKDI001958 Pathological Conditions, Signs and Symptoms Abnormality of the digestive system Disease or Syndrome disease
TCMBANKDI002162 - - Disease or Syndrome disease
TCMBANKDI002231 Digestive System Diseases Abnormality of the digestive system Disease or Syndrome disease
TCMBANKDI002606 Pathological Conditions, Signs and Symptoms; Respiratory Tract Diseases Abnormality of the respiratory system Sign or Symptom phenotype
TCMBANKDI002624 Cardiovascular Diseases - Disease or Syndrome group
TCMBANKDI002974 Neoplasms - Neoplastic Process disease
TCMBANKDI003248 Nutritional and Metabolic Diseases; Endocrine System Diseases Abnormality of metabolism/homeostasis; Abnormality of the endocrine system Disease or Syndrome disease
TCMBANKDI003353 Pathological Conditions, Signs and Symptoms; Neoplasms - Neoplastic Process phenotype
TCMBANKDI003883 Mental Disorders - Mental or Behavioral Dysfunction disease
TCMBANKDI004344 Nervous System Diseases; Endocrine System Diseases - Disease or Syndrome group
TCMBANKDI004450 - Abnormality of metabolism/homeostasis; Abnormal cellular phenotype Anatomical Abnormality disease
TCMBANKDI006328 - Abnormality of the genitourinary system Disease or Syndrome phenotype
TCMBANKDI006406 - - Disease or Syndrome phenotype
TCMBANKDI006612 Neoplasms; Female Urogenital Diseases and Pregnancy Complications Abnormality of the genitourinary system; Neoplasm Neoplastic Process disease
TCMBANKDI008105 Infections; Cardiovascular Diseases - Disease or Syndrome disease
TCMBANKDI009099 Nutritional and Metabolic Diseases; Endocrine System Diseases - Experimental Model of Disease disease
TCMBANKDI009231 Pathological Conditions, Signs and Symptoms; Infections Abnormality of the immune system Disease or Syndrome disease
TCMBANKDI009278 Mental Disorders - Mental or Behavioral Dysfunction group
TCMBANKDI009657 Congenital, Hereditary, and Neonatal Diseases and Abnormalities; Cardiovascular Diseases Abnormality of the cardiovascular system Congenital Abnormality group
TCMBANKDI009911 Pathological Conditions, Signs and Symptoms; Nutritional and Metabolic Diseases; Eye Diseases; Musculoskeletal Diseases; Nervous System Diseases; Cardiovascular Diseases - Disease or Syndrome disease
TCMBANKDI009912 Pathological Conditions, Signs and Symptoms Abnormality of metabolism/homeostasis Sign or Symptom phenotype
TCMBANKDI009951 Nutritional and Metabolic Diseases; Musculoskeletal Diseases Abnormality of the skeletal system Disease or Syndrome disease
TCMBANKDI010160 Respiratory Tract Diseases Abnormality of the respiratory system Disease or Syndrome group
TCMBANKDI010366 Nutritional and Metabolic Diseases - Disease or Syndrome group
TCMBANKDI011173 Neoplasms - Neoplastic Process disease
TCMBANKDI011743 Neoplasms; Skin and Connective Tissue Diseases Neoplasm; Abnormality of the breast Neoplastic Process group
TCMBANKDI011758 - - Laboratory Procedure phenotype
TCMBANKDI012119 Pathological Conditions, Signs and Symptoms Abnormality of the nervous system Cell or Molecular Dysfunction phenotype
TCMBANKDI013313 Pathological Conditions, Signs and Symptoms; Nervous System Diseases Abnormality of the nervous system Sign or Symptom phenotype
TCMBANKDI013541 Cardiovascular Diseases - Disease or Syndrome group
TCMBANKDI013730 Congenital, Hereditary, and Neonatal Diseases and Abnormalities; Cardiovascular Diseases Abnormality of the cardiovascular system Congenital Abnormality disease
TCMBANKDI014088 Respiratory Tract Diseases; Cardiovascular Diseases Abnormality of the respiratory system; Abnormality of the cardiovascular system Disease or Syndrome disease
TCMBANKDI015452 Neoplasms; Endocrine System Diseases Abnormality of the endocrine system; Neoplasm Neoplastic Process disease
TCMBANKDI015485 Mental Disorders Abnormality of the nervous system Mental or Behavioral Dysfunction disease
TCMBANKDI015491 Congenital, Hereditary, and Neonatal Diseases and Abnormalities; Nutritional and Metabolic Diseases; Musculoskeletal Diseases; Nervous System Diseases; Cardiovascular Diseases - Disease or Syndrome disease
TCMBANKDI015932 - - Finding phenotype
TCMBANKDI016612 Mental Disorders Abnormality of the nervous system Mental or Behavioral Dysfunction phenotype
TCMBANKDI016866 Infections; Cardiovascular Diseases - Disease or Syndrome disease
TCMBANKDI017024 Neoplasms; Respiratory Tract Diseases - Neoplastic Process disease
TCMBANKDI017191 Nervous System Diseases; Mental Disorders; Behavior and Behavior Mechanisms Abnormality of the nervous system Sign or Symptom phenotype
TCMBANKDI017952 Congenital, Hereditary, and Neonatal Diseases and Abnormalities; Nutritional and Metabolic Diseases; Nervous System Diseases - Disease or Syndrome disease
TCMBANKDI018731 Digestive System Diseases Abnormality of the digestive system Disease or Syndrome disease
TCMBANKDI018761 - - Diagnostic Procedure phenotype
TCMBANKDI018862 Congenital, Hereditary, and Neonatal Diseases and Abnormalities; Musculoskeletal Diseases; Endocrine System Diseases - Disease or Syndrome disease
TCMBANKDI019825 Neoplasms - Neoplastic Process disease
TCMBANKDI020079 Congenital, Hereditary, and Neonatal Diseases and Abnormalities; Nutritional and Metabolic Diseases - Disease or Syndrome disease
TCMBANKDI020257 Cardiovascular Diseases - Disease or Syndrome disease
TCMBANKDI020373 - Abnormality of the musculature Pathologic Function phenotype
TCMBANKDI020451 Neoplasms - Neoplastic Process disease
TCMBANKDI022361 Pathological Conditions, Signs and Symptoms; Eye Diseases - Sign or Symptom phenotype
TCMBANKDI022433 Respiratory Tract Diseases; Cardiovascular Diseases - Disease or Syndrome disease
TCMBANKDI022757 Nutritional and Metabolic Diseases - Disease or Syndrome disease
TCMBANKDI023834 Nervous System Diseases - Disease or Syndrome group
TCMBANKDI024517 Digestive System Diseases; Neoplasms - Neoplastic Process disease
TCMBANKDI024535 Neoplasms; Respiratory Tract Diseases Neoplasm; Abnormality of the respiratory system Neoplastic Process disease
TCMBANKDI025194 - - Finding disease
TCMBANKDI025420 Digestive System Diseases; Neoplasms Abnormality of the digestive system; Neoplasm Neoplastic Process disease
TCMBANKDI026399 - Abnormality of the cardiovascular system Disease or Syndrome disease
TCMBANKDI027339 Neoplasms; Immune System Diseases; Hemic and Lymphatic Diseases Neoplasm; Abnormality of blood and blood-forming tissues Neoplastic Process disease
TCMBANKDI027406 - Abnormality of the nervous system; Abnormality of the musculature Finding phenotype
TCMBANKDI028237 Digestive System Diseases; Neoplasms - Neoplastic Process disease
TCMBANKDI028799 Eye Diseases - Disease or Syndrome disease
TCMBANKDI028908 Pathological Conditions, Signs and Symptoms; Eye Diseases; Nervous System Diseases Abnormality of the eye Disease or Syndrome phenotype
TCMBANKDI029321 Cardiovascular Diseases - Disease or Syndrome group
TCMBANKDI029791 Nutritional and Metabolic Diseases - Disease or Syndrome phenotype
TCMBANKDI030078 Infections; Nervous System Diseases - Disease or Syndrome disease
TCMBANKDI030540 Neoplasms; Female Urogenital Diseases and Pregnancy Complications; Endocrine System Diseases Abnormality of the genitourinary system; Neoplasm Neoplastic Process disease
TCMBANKDI030716 Pathological Conditions, Signs and Symptoms; Nervous System Diseases Abnormality of the nervous system Finding phenotype
TCMBANKDI031189 Neoplasms Neoplasm; Abnormality of the respiratory system Neoplastic Process disease
TCMBANKDI031192 Neoplasms; Male Urogenital Diseases - Neoplastic Process disease
TCMBANKDI031297 Cardiovascular Diseases - Disease or Syndrome group
TCMBANKDI032222 Nervous System Diseases; Mental Disorders - Mental or Behavioral Dysfunction disease
TCMBANKDI032498 Nutritional and Metabolic Diseases Abnormality of metabolism/homeostasis; Abnormality of the endocrine system Disease or Syndrome disease